Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database

Author:

Reddy Vishruth K.1ORCID,Jain Varsha1,Wilson II Robert J.2,Hartner Lee P.3,Diamond Mark3,Sebro Ronnie A.2456,Weber Kristy L.2,Maki Robert G.3,Shabason Jacob E.1ORCID

Affiliation:

1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

2. Department of Orthopedic Surgery, University of Pennsylvania, Philadelphia, PA, USA

3. Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

4. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA

5. Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA

6. Department of Biostatistics, Epidemiology and Bioinformatics, University of Pennsylvania, Philadelphia, PA, USA

Abstract

Purpose. Practice patterns for treatment of localized adult pleomorphic rhabdomyosarcoma (PRMS) remain quite variable given its rarity. Current national guidelines recommend management similar to that of other high-grade soft tissue sarcomas (STS), which include surgery with perioperative radiation (RT) with or without chemotherapy. Using the National Cancer Database (NCDB), we assessed practice patterns and overall outcomes of patients with localized PRMS. Patients and Methods. Patients with stage II/III PRMS treated with surgical resection from 2004 to 2015 were identified from the NCDB. Predictors of RT and chemotherapy use were assessed using multivariable logistic regression analysis. The association of radiation and chemotherapy status on overall survival was assessed using Kaplan–Meier and Cox proportional hazards analyses. Results. Of 243 total patients, RT and chemotherapy were not uniformly utilized, with 44% receiving chemotherapy and in those who did not undergo amputation 62% receiving RT. In those who did not undergo amputation, RT was associated with improved survival on both univariate (HR: 0.49, 95% CI 0.32–0.73, P < 0.001 ) and multivariate analysis (HR: 0.40, 95% CI 0.26–0.62, P < 0.001 ), corresponding to greater 5-year overall survival (59% vs. 38%, P < 0.001 ). Chemotherapy was associated with a higher rate of 5-year overall survival (63% vs. 39%, P < 0.001 ). However, the survival benefit of chemotherapy did not reach statistical significance on multivariate analysis (HR: 0.65, 95% CI 0.41–1.03, P = 0.064 ). Notable predictors of omission of RT included female gender (OR: 0.40, 95% CI 0.22–0.74, P < 0.01 ) and age ≥ 70 (OR: 0.55, 95% CI 0.30–1.00, P = 0.05 ). Correspondingly, factors associated with omission of chemotherapy included age ≥70 (OR: 0.17, 95% CI 0.08–0.39, P < 0.001 ). Conclusions. A significant proportion of patients with localized adult PRMS are not receiving RT. Likewise, use of chemotherapy was heterogeneous. Our findings note potential benefits and underutilization of RT, for which further investigation is warranted.

Publisher

Hindawi Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3